Bateman Lab

Bateman’s laboratory focuses on the causes, diagnosis and future treatments of Alzheimer’s disease (AD). We directly measure the pathology and pathophysiology of AD in humans using multiple techniques. Our group uses a wide variety of assays and techniques from the most basic applications, such as quantitative measurement of stable-isotope labeled peptides, to clinical translational studies in diagnostic and therapeutic biomarkers for AD.

Randall J. Bateman, MD

Principal Investigator

Randall J. Bateman, MD, is the Charles F. and Joanne Knight Distinguished Professor of Neurology at Washington University School of Medicine, director of the Dominantly Inherited Alzheimer Network (DIAN) and director of the DIAN Trials Unit (DIAN-TU).

Bateman’s laboratory investigates the causes and methods of diagnosis and treatment of Alzheimer’s disease (AD) utilizing a wide variety of assays and techniques from…

Read more

Washington University School of Medicine

Now accepting applications for WashU Medicine Bold Pioneer Award! (Links to an external site)

May 24, 2024

The goal of the $10,000 WashU Medicine Bold Pioneer Award is to recognize and encourage early career investigators who have demonstrated bold, pioneering research that is high-risk by virtue of being fundamentally different from standard approaches. The intent is to encourage scientific research investigators to challenge status quo approaches by developing fundamentally different methods, approaches, […]

NPR, SILQ

New blood tests can help diagnose Alzheimer’s — but some aren’t as accurate as others (Links to an external site)

January 10, 2024

Now that there are drugs to treat Alzheimer’s, blood tests to detect it will likely become an attractive, low-cost option to decide who can get treatment. Some tests are more accurate than others.